Integra LifeSciences (NASDAQ:IART) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.95 and traded as high as $17.73. Integra LifeSciences shares last traded at $17.56, with a volume of 984,868 shares.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IART. Wall Street Zen raised Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Truist Financial cut their price objective on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a report on Wednesday, April 15th. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and increased their price objective for the company from $11.00 to $16.00 in a report on Thursday, May 28th. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Finally, Wells Fargo & Company increased their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Four analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $14.00.

Integra LifeSciences Stock Up 9.1%

The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. The stock has a market cap of $1.37 billion, a P/E ratio of -2.72, a PEG ratio of 1.12 and a beta of 1.24. The firm has a 50-day simple moving average of $12.32 and a two-hundred day simple moving average of $11.95.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. The firm had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities research analysts expect that Integra LifeSciences Holdings Corporation will post 2.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after purchasing an additional 1,975 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Integra LifeSciences in the first quarter worth $277,000. Goldman Sachs Group Inc. increased its position in shares of Integra LifeSciences by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock worth $36,515,000 after purchasing an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Integra LifeSciences by 23.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after purchasing an additional 45,693 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Integra LifeSciences in the second quarter worth $491,000. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.